HHS Secretary's Advisory
Committee on Regulatory Reform
 |
 |
 |
Related Resources
AAMC Documents
|
 |
The Department of Health and Human Services Secretary's Advisory
Committee on Regulatory Reform held its first meeting on Jan.
7-8. The Committee is part of a new Department-wide initiative
to streamline regulatory procedures, particularly in the Centers
for Medicare & Medicaid Services (CMS) and the Food and Drug
Administration (FDA). It is charged with assisting Secretary
Tommy Thompson to "streamline burdensome, inefficient regulations
that interfere with the quality of health care for Americans."
Its underlying objectives are to concentrate on issues where
practical changes can be made to improve the quality of care
for large numbers of patients, and solicit comments from the
public to gather insight from all stakeholders. Douglas Wood,
M.D., a cardiologist from the Mayo Clinic, chairs the Committee.
The Committee will focus on four general areas: health care
delivery, health systems operations, biomedical and health
research, and the development of pharmaceuticals and other
products. Due to the breadth of topics and sheer size of the
committee, subcommittees have been developed to explore issues
more comprehensively and effectively, and will report their
recommendations to the full committee.
Over the next year, the committee is scheduled to meet three
times unless the Secretary determines that additional meetings
are necessary. In addition, committee members will conduct
field hearings across the country. The input and advice compiled
at these hearing will help guide the committee to develop
suggestions for reform. Approximately 30 days following each
meeting, the committee will present its findings in the form
of a written report, and a final report is expected to be
issued in the fall.
Additional information, including membership and scheduling
is available on the Department's Regulatory
Reform Web site. The Department also issued a notice in
the Jan. 4 Federal Register [67
FR 599] soliciting formal public comments to the Committee.
Comments were due by March 5 the AAMC
submitted a letter indicating which issues were most critical
to the community of teaching physicians.
Contact
CMS Regulations: Ivy Baer, Director & Regulatory Counsel
AAMC Health Care Affairs
ibaer@aamc.orc
(202) 828-0490 |
FDA Regulations: [an error occurred while processing this directive] |
|